about us

News

2018

ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards

LOS ANGELES, Oct. 17, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that on October 16, 2018, the Company received notice from the NYSE American LLC ("NYSE American" or the "Exchange") that it has determined to commence proceedings to delist the Company's Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from the Exchange. Trading in the Company's securities on NYSE American has been suspended.

Read entire release »


ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants

LOS ANGELES, Oct. 15, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today notified the NYSE American of its intention to voluntarily withdraw its Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from listing on the NYSE American. ImmunoCellular intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with the Securities and Exchange Commission (the "SEC") on or about October 25, 2018.

Read entire release »


ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

LOS ANGELES, Aug. 13, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, today provided an update on corporate activities and reported financial results for the second quarter ended June 30, 2018.

Read entire release »


ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit

LOS ANGELES, July 19, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that it has reached an agreement in principle to settle the securities class action suit, filed on May 1, 2017 in the United States District Court for the Central District of California, captioned Arthur Kaye IRA FCC as Custodian DTD 6-8-00 v. ImmunoCellular Therapeutics, Ltd. et al., Case No. 2:17-cv-03250, against the Company, certain of its current and former officers and directors, and others.

Read entire release »


ImmunoCellular Therapeutics Announces First Quarter 2018 Financial Results

Los Angeles, CA May 14, 2018 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the first quarter ended March 31, 2018.

Read entire release »


ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

Los Angeles, CA April 12, 2018 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells. This milestone represents the next important step in validating the Stem-to-T-Cell approach, and is a key component of the proof-of-concept work for this technology. This achievement is a key next step to begin preclinical testing. ImmunoCellular's Stem-to-T-Cell technology is designed to stimulate the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects.

Read entire release »


ImmunoCellular Therapeutics Receives Audit Opinion with Going Concern Explanation March 2018

Los Angeles, CA March 26, 2018 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on March 14, 2018, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph (see further discussion in footnote 2 to the Company's financial statements included in the Company's Annual Report on Form 10-K). This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2017.

Read entire release »


ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

Los Angeles, CA March 13, 2018 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the fourth quarter and full year ended December 31, 2017.

Read entire release »


ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018

Los Angeles, CA March 7, 2018 -- ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018

Read entire release »


ImmunoCellular Therapeutics Announces Review of Strategic Alternatives

Los Angeles, CA February 22, 2018 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that it has retained Ladenburg Thalmann & Co. Inc.as its strategic financial advisor to assist in the review of the Company's business and assets and exploration of strategic opportunities for enhancing stockholder value, including the potential sale or merger of the Company. The Company cannot guarantee that this process will culminate in a transaction.

Read entire release »


ImmunoCellular Therapeutics Announces Update on Financial Condition

Los Angeles, CA February 13, 2018 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on its Stem-to-T-Cell research program, announced today that during the fourth quarter ended December 31, 2017, the Company received approximately $5.77 million of gross proceeds from the exercise of warrants in connection with the July 2017 underwritten public offering. The Company ended 2017 with approximately $6.6 million in cash.

Read entire release »


2017

ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

Los Angeles, CA December 13, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. The milestone represents an important step toward stimulating the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects. This approach could be effective in treating many types of cancers.

Read entire release »


ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017

Los Angeles, CA November 22, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Senior Vice President, Research, and David Fractor, Chief Financial Officer, will present at the 10th Annual LD Micro Main Event on Thursday, December 7, 2017 at 9:30 a.m. PT(12:30 p.m. ET) in Track 3. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Read entire release »


ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results

Los Angeles, CA November 21, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced financial results for the third quarter 2017.

Read entire release »


ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017

Los Angeles, CA November 17, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report third quarter 2017 financial results on Tuesday, November 21, 2017. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2017 financial results and provide a business update. The call will be hosted by Anthony Gringeri, PhD, President and CEO.

Read entire release »


ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET

Los Angeles, CA October 3, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Sr. VP, Research, and David Fractor, Chief Financial Officer, will present at the Lytham Partners Virtual Investor Conference on Wednesday, October 11, 2017 at 2:00 p.m. ET(11:00 a.m. PT). The conference is a virtual event that is available over the internet. Interested parties may participate by clicking on either of the links cited below at the time of the conference.

Read entire release »


ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance

Los Angeles, CA September 13, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE MKT: IMUC) today announced that the NYSE MKT LLC (the "NYSE MKT") has accepted the Company's plan to regain compliance with the exchange's continued listing standards set forth in Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE MKT Company Guide (the "Company Guide").

Read entire release »


ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy

Los Angeles, CA August 23, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that it plans to continue strategies to refocus and reallocate its available resources on its promising Stem-to-T-Cell research program. ImmunoCellular's Stem-to-T-Cell program is designed to provide a novel method of harnessing the immune system to manufacture antigen-specific killer T cells that target and destroy cancer cells and provide long-term immuno-surveillance against tumor recurrence. The Stem-to-T-Cell platform has the potential to address many types of cancer, including both solid and hematological tumors.

Read entire release »


ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results

Los Angeles, CA August 14, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the second quarter 2017.

Read entire release »


ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants

Los Angeles, CA July 18, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 5,000 shares of its Series B 8% Mandatorily Convertible Preferred Stock ("Preferred Stock") and related warrants ("Warrants") to purchase up to 9,000 shares of Preferred Stock, at a public offering price of $1,000per share of Preferred Stock and related Warrants, for gross proceeds of approximately $5 million, excluding the proceeds, if any, from the exercise of the Warrants.

Read entire release »


ImmunoCellular Therapeutics Receives Notice from NYSE MKT for Noncompliance with Continued Listing Standards

Los Angeles, CA June 29, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced it has received notification from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders' equity.

Read entire release »


ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial

Los Angeles, CA June 21, 2017 --- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma.

Read entire release »


ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 15, 2017

Los Angeles, CA June 12, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Anthony J. Gringeri, PhD, President and Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conferenceon Thursday, June 15, 2017 at 10:00 am ET at the Grand Hyatt hotel, New York, New York.

Read entire release »


ImmunoCellular Therapeutics Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017

Los Angeles, CA June 5, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the presentation of data from the phase 1 clinical trial of ICT-121 in patients with recurrent glioblastoma.

Read entire release »


ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results

Los Angeles, CA May 15, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the first quarter 2017 and a re-evaluation of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma

Read entire release »


ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology Collaboration

Los Angeles, CA March 23, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) and Memgen, LLC ("Memgen") announce the signing of a non-binding letter of intent to exclusively negotiate the terms to possibly establish an immuno-oncology strategic collaboration focused on conducting clinical trials combining the companies' respective cancer immunotherapy product candidates.

Read entire release »


ImmunoCellular Therapeutics Receives Audit Opinion With Going Concern Explanation

Los Angeles, CA March 14, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 9, 2017, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph (see further discussion in footnote 2 to the Company's financial statements included in the Company's Annual Report on Form 10-K).

Read entire release »


ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Los Angeles, CA March 9, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the fourth quarter and full year 2016 and provided a corporate update.

Read entire release »


ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017

Los Angeles, CA March 6, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2016 financial results on Thursday, March 9, 2017. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the fourth quarter and full year 2016 financial results and provide a business update. The call will be hosted by Anthony Gringeri, PhD, President and CEO.

Read entire release »


ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program

Los Angeles, CA March 6, 2017 -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) today provided an update on the Company's ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, and announced advances in its Stem-to-T-cell Research program.

Read entire release »


2016

December 14, 2016
November 21, 2016
November 16, 2016
November 10, 2016
November 02, 2016
August 22, 2016
August 17, 2016
August 09, 2016
July 25, 2016
June 07, 2016
May 23, 2016
May 12, 2016
May 06, 2016
May 04, 2016
March 30, 2016
March 29, 2016
March 07, 2016
February 16, 2016
February 01, 2016
January 27, 2016


2015

December 14, 2015
December 07, 2015 v-file2
December 07, 2015
December 01, 2015 - file2
December 01, 2015
November 23, 2015
November 20, 2015
November 12, 2015
November 10, 2015
October 27, 2015
September 24, 2015
September 22, 2015
August 21, 2015
August 13, 2015
August 06, 2015
July 23, 2015
July 06, 2015
June 29, 2015
June 22, 2015
June 15, 2015
May 19, 2015
May 11, 2015 - file2
May 11, 2015
May 05, 2015
April 30, 2015
March 19, 2015
March 09, 2015
March 03, 2015
March 02, 2015
February 18, 2015
February 12, 2015
January 28, 2015


2014

December 17, 2014
December 01, 2014
November 14, 2014
November 10, 2014
September 26, 2014
September 24, 2014
September 17, 2014
August 07, 2014
July 29, 2014
June 01, 2014
May 08, 2014
May 01, 2014
April 21, 2014
March 13, 2014
March 11, 2014
March 04, 2014
March 03, 2014
February 25, 2014
February 14, 2014
February 03, 2014
January 13, 2014
January 09, 2014
January 06, 2014


2013

December 23, 2013
December 11, 2013
December 03, 2013
November 24, 2013
November 06, 2013
October 29, 2013
September 17, 2013
September 11, 2013
August 28, 2013
August 07, 2013
August 01, 2013
July 30, 2013
June 07, 2013
June 03, 2013
May 22, 2013
May 16, 2013
May 09, 2013
May 01, 2013
March 28, 2013
March 11, 2013
March 05, 2013
March 04, 2013
February 26, 2013
February 04, 2013
January 29, 2013
January 07, 2013
January 02, 2013


2012

December 03, 2012
November 12, 2012
November 05, 2012
November 01, 2012
October 18, 2012
October 17, 2012
October 02, 2012
September 05, 2012
August 27, 2012
August 20, 2012
August 15, 2012
August 13, 2012
August 08, 2012
July 25, 2012
July 18, 2012
July 10, 2012
July 02, 2012
June 19, 2012
June 18, 2012
May 31, 2012
May 25, 2012
April 18, 2012
April 04, 2012
March 27, 2012
March 22, 2012
March 19, 2012
March 16, 2012
March 12, 2012
March 05, 2012
February 29, 2012
February 21, 2012
February 09, 2012
February 07, 2012
February 01, 2012
January 30, 2012
January 23, 2012
January 17, 2012
January 10, 2012


2011

October 10, 2011
October 06, 2011
October 05, 2011
October 03, 2011
September 28, 2011
September 09, 2011
September 07, 2011
August 29, 2011
August 03, 2011
June 22, 2011
June 21, 2011
June 08, 2011
June 02, 2011
May 24, 2011
May 05, 2011
April 15, 2011
March 31, 2011
February 23, 2011
February 11, 2011
February 02, 2011
January 04, 2011


2010

December 08, 2010
October 13, 2010
October 07, 2010
October 05, 2010
September 16, 2010
September 08, 2010
September 03, 2010
August 17, 2010
July 08, 2010
June 22, 2010
June 14, 2010
June 11, 2010
June 02, 2010
May 26, 2010
May 17, 2010
May 03, 2010
April 21, 2010
April 13, 2010
April 01, 2010
March 23, 2010
March 17, 2010
March 10, 2010
March 02, 2010
February 04, 2010
January 20, 2010
January 08, 2010


2009

December 11, 2009
December 07, 2009
December 02, 2009
December 01, 2009
November 19, 2009
November 17, 2009
October 27, 2009
October 22, 2009
October 19, 2009
September 30, 2009
September 23, 2009
September 17, 2009
September 09, 2009
September 03, 2009
August 17, 2009
July 14, 2009
June 29, 2009
June 24, 2009
June 18, 2009
May 26, 2009
March 31, 2009
March 10, 2009
February 24, 2009


2008

December 23, 2008
November 05, 2008
October 21, 2008
October 14, 2008
October 09, 2008
September 23, 2008
July 23, 2008
July 09, 2008
June 25, 2008
June 19, 2008
June 11, 2008
May 28, 2008
May 21, 2008
May 13, 2008
March 26, 2008
February 21, 2008
February 15, 2008


2007

November 26, 2007 - file2
November 26, 2007
November 13, 2007
August 02, 2007

Copyright 2019 by Immunocellular Therapeutics, Ltd.
All Rights Reserved